麒盛科技：10月24日召开董事会会议

Group 1 - The company Qisheng Technology announced that its 34th meeting of the third board of directors will be held on October 24, 2025, to review documents including a proposal for providing guarantees for its controlling subsidiary [1] - The Chinese innovative pharmaceutical industry has sold overseas licenses worth $80 billion this year, indicating a strong performance in the secondary market for biomedicine [1] - Despite the robust activity in the secondary market, the primary market is experiencing a cooling in fundraising, as noted by Lu Gang, a partner at Chuangdong Investment [1]